Patents by Inventor Philip G. Kasprzyk

Philip G. Kasprzyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inhibiting fibrosis with a somatostatin agonist
    Patent number: 7238666
    Abstract: The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patent.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: July 3, 2007
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S
    Inventors: Michael D. Culler, Philip G. Kasprzyk
  • Therapeutic composition containing at least diflomotecan and capecitabine
    Publication number: 20040259834
    Abstract: The method of treating cancer by administering to a patient in need thereof a synergistic effective amount of a composition comprising at least a first component of diflomotecan and a second component of capecitabine.
    Type: Application
    Filed: June 18, 2003
    Publication date: December 23, 2004
    Inventors: Philip G. Kasprzyk, Gregoire Prevost, Paola Principe-Nicolas
  • Method of inhibiting fibrosis with a somatostatin agonist
    Patent number: 6787521
    Abstract: The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or a pharmaceutically acceptable salt thereof to said patent.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: September 7, 2004
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Michael D. Culler, Philip G. Kasprzyk
  • Method of inhibiting fibrosis with a somatostatin agonist
    Publication number: 20010011072
    Abstract: The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or a pharmaceutically acceptable salt thereof to said patent.
    Type: Application
    Filed: January 16, 2001
    Publication date: August 2, 2001
    Applicant: Biomeasure, Incorporated
    Inventors: Michael D. Culler, Philip G. Kasprzyk
  • Method of inhibiting fibrosis with a somatostatin agonist
    Patent number: 6268342
    Abstract: The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patient.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: July 31, 2001
    Assignee: Biomeasure Incorporated
    Inventors: Michael D. Culler, Philip G. Kasprzyk
  • Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
    Patent number: 5587458
    Abstract: The present invention relates to novel antibodies, in particular monoclonal and single chain antibodies derived therefrom which specifically bind to erbB-2, as well as diagnostic and therapeutic uses thereof. The present invention also relates to a combination of at least two erbB-2 specific antibodies which are capable of preventing and treating human malignancies wherein the malignant cells overexpress gp185.sup.erbB-2. The monoclonal antibodies of the combination preferably recognize different epitopes of the gp185 expression product of erbB-2, therefore, the antibodies do not cross react with each other. Preferably, the combination will provide for synergistic decrease in the expression of the erbB-2 gene product.
    Type: Grant
    Filed: May 14, 1993
    Date of Patent: December 24, 1996
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: C. Richter King, Philip G. Kasprzyk, Robert E. Bird